{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.8","upperLimit":"94.8","value":"91.3"},{"groupId":"OG001","lowerLimit":"88.4","upperLimit":"96.5","value":"93.6"},{"groupId":"OG002","lowerLimit":"84.9","upperLimit":"94.2","value":"90.6"},{"groupId":"OG003","lowerLimit":"81.9","upperLimit":"92.2","value":"88.1"}]}],"title":"24 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.0","upperLimit":"92.3","value":"88.1"},{"groupId":"OG001","lowerLimit":"79.6","upperLimit":"90.8","value":"86.2"},{"groupId":"OG002","lowerLimit":"78.7","upperLimit":"90.0","value":"85.3"},{"groupId":"OG003","lowerLimit":"73.9","upperLimit":"86.3","value":"80.9"}]}],"title":"36 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.9","upperLimit":"86.3","value":"81.0"},{"groupId":"OG001","lowerLimit":"76.4","upperLimit":"88.5","value":"83.4"},{"groupId":"OG002","lowerLimit":"74.7","upperLimit":"87.1","value":"81.8"},{"groupId":"OG003","lowerLimit":"67.3","upperLimit":"81.0","value":"74.9"}]}],"title":"48 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.4","upperLimit":"82.7","value":"76.8"},{"groupId":"OG001","lowerLimit":"73.1","upperLimit":"86.0","value":"80.5"},{"groupId":"OG002","lowerLimit":"68.2","upperLimit":"82.0","value":"75.9"},{"groupId":"OG003","lowerLimit":"64.1","upperLimit":"78.4","value":"72.0"}]}],"title":"60 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.9","upperLimit":"77.5","value":"70.9"},{"groupId":"OG001","lowerLimit":"68.7","upperLimit":"82.7","value":"76.6"},{"groupId":"OG002","lowerLimit":"65.6","upperLimit":"80.0","value":"73.6"},{"groupId":"OG003","lowerLimit":"62.5","upperLimit":"77.1","value":"70.5"}]}],"title":"72 Months (n=167, 167, 168, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.1","upperLimit":"71.8","value":"64.6"},{"groupId":"OG001","lowerLimit":"65.2","upperLimit":"79.9","value":"73.4"},{"groupId":"OG002","lowerLimit":"62.0","upperLimit":"77.1","value":"70.3"},{"groupId":"OG003","lowerLimit":"59.8","upperLimit":"74.9","value":"68.1"}]}],"title":"84 Months (n=167, 167, 168, 168)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"168"},{"groupId":"OG003","value":"168"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.\n\nAfter the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All participants who were randomized to a treatment arm were summarized.","reportingStatus":"POSTED","timeFrame":"24, 36, 48, 60, 72, and 84 months","title":"Percent of Participants Overall Survival at 24, 36, 48, 60, 72, and 84 Months Follow-Up - All Randomized Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}